Address: Av. Cordoba 934 Piso 1 (C1054AAV), Buenos Aires,Argentina
Tel: +54 11 4322 2602/03/04
Web: http://www.foarbi.org.ar/ppal/
Biotechnology is an industry that is currently booming in Argentina. And the Argentinean Biotechnology Forum (FAB) is an association that works ceaselessly within Argentina to connect biotechnology research to businesses and government, helping all three come together in order to pursue the Argentinean national interest. FAB represent companies in both the agribusiness side of biotechnological research, and also the healthcare sector. FAB’s work includes seminars, workshops, and international events, all designed to push the biotech agenda within the country.
Government Policy, Scientific/Business Networking
Pierre Fabre has been present in the Moroccan market for nearly 40 years. Pierre Behnam, the company’s director for Africa, Middle-East and Türkiye discusses its strategy for bringing innovation and…
French-headquartered Pierre Fabre has merged its dermo cosmetics and medical care arms under a single management team over the past four years; a strategy that has helped the firm to…
Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth…
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In…
Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the…
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and…
Pierre Fabre’s recently appointed head for Africa, the Middle East and Turkey, Mouloud Boukhachab, outlines his career trajectory, having worked and managed in geographies as diverse as BeNeLux and Morocco.…
Pierre Behnam, general manager of Pierre Fabre in Morocco, breaks down the strong and long-standing footprint of the group in the country in the medical and dermo-cosmetic fields. On the…
Jean Nève and Fabrice Peters, president and general coordinator of the Belgian Superior Health Council (SHC), introduce the organization, elaborate on its role in helping guide the country’s healthcare policy,…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pierre Fabre, the French dermo-cosmetics giant, is banking on its tradition of quality to continue disrupting the emerging markets. Naim Hanna, managing director for the Middle East and Gulf region,…
Kirsch Pharma is a raw materials provider to the pharmaceutical, nutritional, biotechnology, veterinary and cosmetic industries. The business in China was established in 1997, importing high-quality raw materials from Germany.…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic…
* Dr Fabrizio Guidi has left his role as country chair & general manager Rx of Sanofi Turkey and is currently Sanofi’s general manager of diabetics and cardiovascular for Germany, Switzerland…
Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company…
Frederic Charles, CEO of Pierre Fabre Hong Kong and Macau, outlines brand perceptions of Pierre Fabre’s dermatological products in Hong Kong, e-commerce, and other emerging skincare trends in Asia. …
Nawel Baba Hamed, general director of Pierre Fabre Algeria, outlines the French company’s product portfolio in Algeria, its dermatological expertise, and the growing significance of its oncology segment. Could…
Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the…
Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the…
Philippe Coudiere, general manager of Pierre Fabre Dermo-cosmetics Poland, highlights the key partnerships the company has nurtured with pharmacists and dermatologists and the importance of clinical data for their products.…
Alex Carvalho, general manager Pierre Fabre Brazil, provides insights into the rapidly ascending trajectory of the company in Brazil, its utmost commitment to oncology in the country, and Pierre Fabre’s…
Linda Tibbits, general manager at Pierre Fabre Dermo-Cosmetics in Canada takes us back to the beginnings of the French company in the country, where its initial success was driven by…
Hamouda Zaouia, regional manager Africa, Middle East and Turkey, and Khaled Laouiti, general manager Tunisia, Libya and sub-Saharan Africa, stress the important strategic position the African continent has for Pierre…
Fabrice Barbu, general manager of Servier Tunisia, discusses how Servier wants to build a strong presence in the oncology field in Tunisia and is currently investigating the possibilities of bringing…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
“Robust solutions, the capability to implement them and the ability to do so globally” – The executive president of product and brand protection solutions at SICPA explains why the company…
Outspoken, charismatic and dedicated General Manager of Pierre-Fabre Greece, Philippe Lambrinos, shares his insights on the company’s presence and performance in the challenging Greek market, how it’s manoeuvring issues of…
Pierre Fabre Medicament’s MD for Asia Pacific, Ng Tian Wee, on the growing importance of the region for PF, the significance of choosing Singapore as a regional hub, and the…
Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet…
AFKLM Cargo’s Director Pharma, Renate de Walle and Sales & Business Developer Manager Pharma France, Fabrice Panza speak about AFKLM Cargo recently achieved IATA Centre of Excellence for Independent Validators…
Karel Fucikovsky, general director PFM Latin America at Pierre Fabre, on the strategic focus of the company on operational and commercial excellence in Mexico and Latin America, which both stand as…
Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role…
Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to…
Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the…
Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the…
Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014:…
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
The CEO of Pierre Fabre for South Africa reveals how his focus has been on marketing the company brand locally, why the goal of the company is to develop business…
The CEO and president of Smart Scale explains how the company delivers clever and innovate information technology services to the pharmaceutical industry, acting as a significant partner for both information…
One of the so-called ‘new generation’ of pharmaceutical GMs in Romania outlines his first impressions of the local market and details how MSD has managed to shape in-county developments in…
In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its…
Smart Scale was recently certified and recognized for its international quality standards. What have been the main growth drivers? Our experience and deep knowledge of the pharmaceutical market has been…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Apart from MNCs, there are many local businesses that are rather strong in the Romanian pharmaceutical market. Could you give our readers an idea of their main strengths? There is…
Please can you give us a brief rundown of Pierre Fabre’s activities in Mexico since they opened an affiliate here, specifically the company’s milestones and achievements along the way? Pierre…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Finderm is the result of a courageous entrepreneurial experience, since you initiated the operations in 1995, in the most challenging times for the Italian pharmaceutical industry. Could you briefly introduce…
You have been in S. Korea for a little over a year, following international assignments in Vietnam and Thailand. Besides the fact that this is a much bigger market, what…
“In the last decade, as a result of high and sustained growth, the Argentine pharmaceutical industry increased production by more than 240 percent, which speaks volumes about the capacity of…
The country president of AstraZeneca Argentina discusses the country’s patent laws, the work being done to bring innovation back to Argentina, and the challenge of a strong branded generics market…
When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a…
Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura…
The executive management of Nycomed said in an interview that ‘the tremendous growth of the pharmaceutical industry will not occur in either Europe or the United States, but in emerging…
Could you give us an overview of the generics sector in Argentina as it stands at the moment? The generics market in Argentina was started immediately after the regulation regarding…
Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on…
What have been the recent major milestones for Richmond? One of the milestones for Laboratorios Richmond was to have developed the first branded oncological generic in the world. For Laboratorios…
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
What was the vision behind the creation of the umbrella organisation Amega Biotech in 2005? What led you to consider setting up an organisation with this structure, and offering these…
UNC HEMODERIVADOS tiene una estructura muy especial y única con su asociación con la Universidad de Córdoba. ¿Cual fue la visión cuando se creó la empresa? El Laboratorio UNC Hemoderivados…
What has been the history of Massone in Argentina and how has it changed since you took over the company? Since the creation of the company by my grandfather I…
See our Cookie Privacy Policy Here
